To the Editor:
Leukemia cells show an altered transcriptome and proteome that can be associated to many genetic and epigenetic defects. Adding complexity to the biology of transformed cells and its RNA and protein landscape, it has recently been shown that cancer cells also exhibit a distorted pattern of chemical modifications of the RNA molecule [1, 2], the so called epitranscriptome. More than 150 differentially modified nucleotides have been reported in various RNA species, affecting transcript structure, stability, splicing, nuclear export, targeting or translational efficiency [1, 2]. The most abundant internal modification of messenger RNA (mRNA)  is the methylation of adenosine (A) in the form of m6A, affecting numerous features of RNA activity and metabolism . The identification of an m6A eraser, FTO , represented the first proof of a reversible mRNA modification and has further stimulated epitranscriptome research in cellular differentiation and carcinogenesis. Since then, the molecular pathways of m6A have been carefully dissected revealing that the mark is established by an RNA methyltransferase writer complex with a catalytic subunit, METTL3 and several assistant proteins (METTL14, WTAP, RBM15, KIAA1429, and ZC3H13) . In addition to FTO, m6A can also be reversed by ALKBH5 . The m6A mark is “read” by m6A-binding proteins, such as members of the YTH family (YTHDF1-3 and YTHDC1-2), IGF2BP1-3 proteins, and heterogeneous nuclear ribonucleoproteins (hnRNPs) .
In hematopoiesis, the generation of all the different types of mature blood cells from hematopoietic stem cells (HSCs) requires a tight control of RNA activity and disrupted patterns of m6A RNA modification and alterations in its associated proteins impair physiological hematopoiesis and are also observed in hematological malignancies [6,7,8]. In this regard, m6A marking was shown to be important for the resolution of the naive state of embryonic stem cells to primed cells, the control of cell fate decisions in early hematopoiesis and the maintainance of hematopoietic stem cell identity and symmetric commitment [8, 9]. Less is known about the role of m6A RNA decoration in transition of differentiated stages of more mature hematopoietic cells in physiological and pathological microenvironmental conditions. Examples of hematopoietic cell lineage conversion and plasticity include B-cell lymphomas that transdifferentiate to histiocytic/dendritic cell sarcoma and B-cell acute lymphoblastic leukemia (ALL) patients that escape both antibody treatments and chimeric antigen receptor (CAR) T-cell therapy against CD19 by converting to AML. We have recently identified that myeloid-lineage transdifferentiation is associated with a reconfiguration of the DNA methylation landscape . We now investigated whether such transdifferentiation also involves a switch in the m6A RNA epitranscriptome.
Our experimental model involves transdifferentiation of pre-B cells into macrophages. Following early work showing that murine B-cell precursors can be induced by C/EBPα to convert into functional macrophages, we used murine and human cellular models of pre-B cells containing C/EBPα fused with the estrogen receptor hormone-binding domain (C/EBPαER) that transdifferentiate to macrophages upon 17β-estradiol exposure [11, 12]. Primary human BCR-ABL1(+) B-ALL cells can also be reprogrammed into macrophage-like cells by C/EBPα expression . To identify possible remodeling of the m6A RNA landscape upon cell conversion, we have herein studied the human precursor B-ALL cell line RCH-ACV transfected with the transgene C/EBPαER, designated below as BLaER1, at the start (0 h) and end (168 h) of transdifferentiation timepoints upon 17β-estradiol exposure, using m6A-sequencing (m6A-seq) based on immunocapturing and massive parallel sequencing (Supplementary Methods) . The obtained m6A-seq raw data have been deposited in the Sequence Read Archive (SRA) BioProject (accession number PRJNA734010).
m6A profiling of efficiently transdifferentiated cells, which was validated by the shift in the corresponding CD19 and CD11B markers (Fig. 1A) and additional B-cell and macrophage markers (Fig. S1), revealed that whereas 406 m6A peaks (corresponding to 326 transcripts) were stable between the 0 h and 168 h time points, 6072 m6A peaks corresponding to 3056 RNA transcripts changed upon cell conversion (Dataset 1). Thus, 94% of the detectable m6A peaks changed upon transdifferentiation, indicating that transformation of pre-B ALL cells to macrophages induced profound remodeling of the m6A RNA methylome. As to the precise location within the RNA molecule of these m6A peaks, 62.5% (3796) were localized in gene-body related sequences, corresponding to 31.6% (1922) and 30.9% (1874) intron and exon RNA sequences, respectively; whereas 19% (1153) were in 5′-untranslated regions (UTRs) and 18.5% (1123) in 3′-UTRs (Fig. 1B). Cell conversion lead to losses in 3192 (52.6%) m6A peaks corresponding to 1560 transcripts, and a gain of m6A for 2,880 sites (47.4%) corresponding to 1664 transcripts (Fig. 1B). Thus, both m6A RNA hypomethylation and hypermethylation events are observed at similar frequencies during transdifferentiation. These results fit with an observed downregulation of both “eraser” and “writer” proteins for the m6A mark upon transdifferentiation (Fig. S2).
To further study the identified set of 3056 gene transcripts with significantly distinct m6A content upon cell transdifferentiation, we performed functional gene annotation by gene set enrichment analysis (GSEA). We observed an overrepresentation of Gene Ontology (GO) biological processes, molecular function, KEGG pathways and reactome pathways related to RNA ribosome protein translation, such as “ribosome biogenesis”, “ribosomal RNA processing”, “nucleolus”, “translation” and “ribosome”; in addition to RNA regulation (such as “RNA binding” and “RNA transport”) (Fig. 1C) [hypergeometric test with a false discovery rate (FDR) adjusted p < 0.05]. Interestingly, when we stratified by up and down m6A targets, it was the gain of m6A in transdifferention that was associated with GO RNA ribosome protein translation pathways, whereas m6A loss was linked to other processes such as transcriptional regulation, splicing and chromatin modifications (Fig. S3). These processes highlight a role for m6A as a major contributor to shape the gene expression landscape and, thus, to provide cellular identity.
One key issue related to the impact of m6A marks in mRNA function relates to the location of the modification [1, 2]. The first and best-recognized activity of m6A is to induce mRNA instability , particularly when deposited at 3′-UTRs [1, 2, 4]. To study the effect of identified differential 3′-UTR m6A sites on gene expression in our model, we took advantage of the available microarray expression data of the start (0 h) and end (168 h) cell conversion timepoints . We did not observe any overall association between the presence of m6A peaks and expression levels (Fisher’s exact test, 2-Tail, P value = 0.78), even when stratified for losses and gains of m6A vs upregulation or downregulation of the corresponding transcripts (Fisher’s exact test, 2-Tail, P value = 0.29) (Fig. S4). We observed, in agreement with the previously published literature [1, 2, 4], that an increase in 3′-UTR m6A sites was associated with transcript downregulation, taking into consideration the 742 m6A peaks that exhibited a corresponding transcript in the expression microarray (Fisher’s exact test, 2-Tail, P value = 0.017). Most importantly, and in agreement with the GO results (Fig. 1C and Fig. S3), we found an enrichment in genes related to protein ribosome translation for these transcripts enriched by m6A at their 3′-UTR (Fisher’s P value = 1.2 × 10e−13). Among these genes, many ribosomal proteins are some of the most significantly downregulated upon m6A 3-UTR increased deposition accompanying the transdifferentiation process (Dataset 2). We further validated by Quantitative Reverse Transcription PCR (qRT-PCR) the seven top genes in this category (RPS25, RPL23A, RPS3, RPS21, RPS27, RPS14, and RPL3) and we confirmed their significant downregulation at the end of the cell conversion (Fig. 2A). Importantly, using the Actinomycin D assay to determine the mRNA stability of our top candidate RSP25, which is downregulated at the RNA (Fig. 2A) and protein (Fig. S5) levels in our model, we observed that transdifferentiation induced a reduction of transcript stability (Fig. S5). This results is in agreement with the proposed role of a gain of m6A mark in the 3′-UTR [1, 2, 4]. Interestingly, cells in a middle time point of the conversion process (72 h) show intermediate values for all the above-described parameters (B-cell vs macrophage markers, m6A-seq, and ribosomal protein expression patterns) (Fig. S6), supporting that the described transdifferentiation model reflects a gradual change from one cell type to the other.
Having shown the above associations that support a functional role for m6A in pre-B cell to macrophage transdifferentiation, particularly targeting 3′-UTRs of ribosome-associated transcripts, we experimentaly validated this model by knocking down the main m6A RNA methyltransferase, METTL3 . Efficient shRNA-mediated downregulation of METTL3 in the BLaER1 pre-B cells using three different target sequences (Fig. 2B and Fig. S7) lead to a significant decrease in transdifferentiation rate as measured by B-cell and macrophage markers (Fig. 2C and Fig. S7). The impairment of transdifferentiation was maintained even at 240 h (Fig. S8). Remarkably, the inefficient induction of cell conversion in the METTL3 knockdown model leads to an increase in cell growth and reduced apoptosis that is associated with the predominance of the proliferating B-ALL cells that cannot commit to macrophage transdifferentiation (Fig. S9). Interestingly, the use of STM2457, a METTL3 drug inhibitor , mimicked the METTL3 shRNA results by also reducing m6A content and impairing transdifferentiation (Fig. S10). Most importantly, METTL3 knockdown cells did not exhibit m6A-mediated downregulation of the seven ribosomal proteins observed in our B-cell to macrophage conversion model (Fig. 2A), that instead were upregulated in comparison to the empty-vector-transduced cells (Fig. 2D and Fig. S11). Interestingly, the sorted out population of successfully transdifferentiated CD19-/CD11B+ cells upon METTL3 knockdown showed partial upregulation of ribosomal proteins, 4 of 7 (57%) (Fig. S12). Finally, METTL3 knockdown cells, showing reduction of the overall m6A mark, exhibited an increased stability of the RPS25 mRNA transcript according to the Actinomycin D assay (Fig. S13).
Overall, these results indicate a relevant activity of m6A RNA marks in the succesfull generation of a macrophage from pre-B cells, particularly by decorating the 3′-UTRs of genes related to the ribosome translational machinery. These findings highlight the role of this epitranscriptomic signal, and the proteins controling and mediating its deposition and downstream effects, in hematological transdifferentiation pathways.
Lian H, Wang QH, Zhu CB, Ma J, Jin WL. Deciphering the epitranscriptome in cance. Trends Cancer 2018;4:207–21.
Davalos V, Blanco S, Esteller M. SnapShot: messenger RNA modifications. Cell 2018;174:498–498.
Huang H, Weng H, Chen J. The biogenesis and precise control of RNA m6A methylation. Trends Genet. 2020;36:44–52.
Jia G, Fu Y, Zhao X, Dai Q, Zheng G, Yang Y, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011;7:885–7.
Vu LP, Cheng Y, Kharas MG. The biology of m6A RNA methylation in normal and malignant hematopoiesis. Cancer Discov. 2019;9:25–33.
Rosselló-Tortella M, Ferrer G, Esteller M. Epitranscriptomics in hematopoiesis and hematological malignancies. Blood Cancer Discov. 2020;1:26–31.
Qing Y, Su R, Chen J. RNA modifications in hematopoietic malignancies: a new research frontier. Blood. 2021;138:637–48.
Zhang C, Chen Y, Sun B, Wang L, Yang Y, Ma D, et al. m6A modulates haematopoietic stem and progenitor cell specification. Nature. 2017;549:273–6.
Cheng Y, Luo H, Izzo F, Pickering BF, Nguyen D, Myers R, et al. m6A RNA methylation maintains hematopoietic stem cell identity and symmetric commitment. Cell Rep. 2019;28:1703–1716.
Bueno-Costa A, Piñeyro D, Soler M, Javierre BM, Raurell-Vila H, Subirana-Granés M, et al. B-cell leukemia transdifferentiation to macrophage involves reconfiguration of DNA methylation for long-range regulation. Leukemia. 2020;34:1158–62.
Bussmann LH, Schubert A, Vu Manh TP, De Andres L, Desbordes SC, Parra M, et al. A robust and highly efficient immune cell reprogramming system. Cell Stem Cell. 2009;5:554–66.
Rapino F, Robles EF, Richter-Larrea JA, Kallin EM, Martinez-Climent JA, Graf T. C/EBPα induces highly efficient macrophage transdifferentiation of B lymphoma and leukemia cell lines and impairs their tumorigenicity. Cell Rep. 2013;19:1281.
McClellan JS, Dove C, Gentles AJ, Ryan CE, Majeti R. Reprogramming of primary human Philadelphia chromosome-positive B cell acute lymphoblastic leukemia cells into nonleukemic macrophages. Proc Natl Acad Sci USA. 2015;112:4074–9.
Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485:201–6.
Sommer S, Lavi U, Darnell JE Jr. The absolute frequency of labeled N-6-methyladenosine in HeLa cell messenger RNA decreases with label time. J Mol Biol. 1978;124:487–99.
Yankova E, Blackaby W, Albertella M, Rak J, De Braekeleer E, Tsagkogeorga G, et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature. 2021;593:597–601.
We thank CERCA Programme/Generalitat de Catalunya for institutional support. This work was supported by the Health Department PERIS-project no. SLT/002/16/00374 and AGAUR-projects no. 2017SGR1080 of the Catalan Government (Generalitat de Catalunya); Ministerio de Ciencia e Innovación (MCI), Agencia Estatal de Investigación (AEI) and European Regional Development Fund (ERDF) project no. RTI2018-094049-B-I00; the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (Grant agreement No. 743168); the Varda and Boaz Dotan Research Center in Hemato-oncology affiliated to the Tel Aviv University; the Cellex Foundation; and “la Caixa” Banking Foundation (LCF/PR/GN18/51140001). ME is an ICREA Research Professor.
ME is a consultant of Ferrer International and Quimatryx. NAW and BA are employees of STORM Therapeutics Ltd. The remaining authors declare that they have no conflict of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Bueno-Costa, A., Piñeyro, D., García-Prieto, C.A. et al. Remodeling of the m6A RNA landscape in the conversion of acute lymphoblastic leukemia cells to macrophages. Leukemia 36, 2121–2124 (2022). https://doi.org/10.1038/s41375-022-01621-1